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Abstract
Fever during chemotherapy-induced neutropenia continues to be a major cause of morbidity and mortality in
cancer patients. Mortality depends on the duration and degree of neutropenia, bacteremia, sepsis, performance status,
comorbidities and other parameters. The highest mortality rates in cancer patients hospitalized with febrile neutropenia
(FN) are observed in those with documented infection. The objectives of the study were to present available tools for
risk assessment, to review pathogens causing infections in adult FN patients and to assess outcomes. Methods: This
cross sectional study was conducted on adult culture positive FN patients admitted to the Hematology/Oncology
service at the Aga Khan University Hospital, Karachi, Pakistan from 1st January 2009 to 31st December 2012. Highrisk criteria were defined as profound neutropenia, short latency from a previous chemotherapy cycle, sepsis or
clinically documented infection at presentation, severe co-morbidity and a performance status greater than or equal
to 3. All types of organisms in blood culture and the outcomes of the patients were recorded on Proforma. Results:
A total of 156 patients with culture-positive febrile neutropenia were identified during the study period. The mean
age was 47 years with a slight male predominance of 54%. One hundred and sixteen patients fulfilled the criteria for
the high risk group. Fifty two percent had a single high risk factor and 40 % had two. All patients harbored either
single or multiple bacterial organisms including gram positive, gram negative or both types. Some 34% of patients
had gram positive bacteremia, 57 % had gram negative and 9 % were infected with both. Among 73 gram positive
cultures 44 % were Staphylococcus species and among 123 gram negative cultures 43 % were E. coli. One hundred
and fifteen patients recovered uneventfully and could be discharged. Thirty two patients in the high risk and 9 in the
low risk groups deceased with an overall mortality of 26 %. The mean hospital stays of patients with solid tumors and
hematological malignancies were 7.58 and 15.0 days, respectively. Mortality was higher in the latter group, and also
in high risk patients with both gram positive and negative bacteremia. Conclusion: We emphasize the importance of
risk stratification and continuous surveillance of the spectrum of locally prevalent pathogens and their susceptibility
patterns for formulation of therapeutic regimens for febrile neutropenic patients.
Keywords: Febrile neutropenia (FN)- high risk (HR)- outcomes
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Introduction
Fever during chemotherapy-induced neutropenia
continues to be a major cause of morbidity and mortality
in cancer patients (Meunier et al.,1990). Although it is
Potentially serious and may lead to a lethal outcome,
yet many patients respond quickly to broad empiric
spectrum antibiotic treatment and exibit an indolent
course. However, 2 to 10% of patients develop severe
complications and eventually die before resolution
of the episode. Even for those patients who recover,it
is also associated with increase in costs of anticancer
treatments and may adversely affect patients quality of life.
(Paesmans et al., 2007). Over the past few decades there
has been considerable change in the pattern of pathogens
causing infections in FN. Staphylococcus aureus was the

most frequent bacterial isolate from these patients in 1950s
and early 1960s but was later replaced by Gram- negative
bacilli organisms including Escherichia coli, Klebsiella
species and Pseudomonas aeruginosa (Jones et al., 1999).
However, since 1980s, resurgence of Gram-positive
organisms is evident in these patient population (Sharma
et al., 2005). Recently reports from developing countries
have shown continued predominance of Gram negative
bacilli in FN (Kanafani et al., 2007; Baskaran et al., 2007).
Mortality in FN has been shown to be associated with
several factors like duration and degree of neutropenia,
bacteremia, isolation of resistant organisms, identifiable
focus (e.g., pneumonia, soft tissue infections, or catheter
related infections), performance status, comorbidities,
type and advance stage of underlying malignancy, etc.
Though, these criteria are mostly used to stratify FN

Department of Oncology, Aga Khan University Hospital, Karachi, Pakistan. *For Correspondence: osmaniasif77@gmail.com
Asian Pacific Journal of Cancer Prevention, Vol 18

2741

Asif Husain Osmani et al

episodes into low risk or high risk with implications for
its management as inpatient or as outpatient , respectively
(Klastersky et al., 2000) ; still, these are rather less well
defined for those who are high-risk patient being treated
as inpatient (Kuderer et al., 2006).
The mortality rate for cancer patients with FN averaged
9.3% per hospital database (range, 0% to 50%), with
as much as 35.5% of institutions reporting mortality
rates of 10% or greater.8 The overall mortality in our
previous study was 13.7% (Osmani et al., 2012) . The
highest mortality rates in cancer patients hospitalized
with FN were observed with infections such as invasive
fungal infections like, aspergillosis (39.2%) and invasive
candidiasis (36.7%) followed by Gram-negative sepsis
(33.9%), pneumonia (26.5%) or Gram-positive sepsis
(21.2%), and those patients with major co-morbid
conditions (Kuderer et al., 2006).
The objective of the study is to present the available
tools for risk assessment, and to review the patterns of
pathogens in adult febrile neutropenic patients and to see
their outcomes based on mortality.

Materials and Methods
This cross sectional study was conducted on adult
patients with culture positive FN admitted under
Hematology/Oncology service at Aga Khan University
Hospital, Karachi, Pakistan from 1st January 2009 to
31st December 2012. The data set included patients
demographics; age, sex and types of cancers; ANC at
presentation; High-risk or low risk. High risk criteria were
defined as: profound neutropenia (ANC <100/mm3), short
latency from previous chemotherapy cycle (<10days),
sepsis or clinically documented infection at presentation,
severe co morbidity, performance status greater than or
equal to 3 [Eastern Cooperative Oncology Group -ECOGscale. An ERC (Ethics Review Committee) approval
was taken and later all the information was recorded
on pretested Performa. All febrile neutropenic patients
were treated initially empirically with broad spectrum
intravenous antibiotics which were modified later based
on culture results. However, decision of vancomycin and
amphotericin B was according to established guidelines
for the management of febrile neutropenia. All patients
were managed in the oncology unit while neutropenic
septic shock patients were managed in intensive care unit.
The data was retrieved through the data was retrieved
through hospital’s registration system and was analyzed
by using Statistical Package for Social Sciences (SPSS)
Version 19. Frequencies and percentages were computed
for baseline characteristics, risk factors, bacterial isolates
and outcome.

Results
Total of 156 patients with culture positive febrile
neutropenia were identified during the study period. The
mean age was 47 (SD±11) years and there was a slight male
predominance 54 % and females 46 % respectively. The
proportion of distribution of patients was equal between
solid and hematological malignancies. However, among
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Table 1. Baseline Demographic and Clinical
Characteristics of Febrile Neutropenic Patients
Characteristics
Age in years

No. of Patients, n=156
47 years (SD ±16)

Number of hospital stay in days
Solid tumor
Hematological Malignancy
Gender, Male/Female

11 (SD ± 11)
7.58 (SD±6.22)
14.95(SD±11.76)
84/72

Outcome (Percentage)
Alive

115 (74 %)

Dead

41 (26%)

Cancer type:
Solid n=78 (50%)
Head & Neck

08 (10%)

Breast

14 (18%)

Lung

07 (09%)

Gastrointestinal malignancy

19 (24%)

Genitourinary

16 (21%)

Germ cell tumor

02 (03%)

Sarcoma

09 (11%)

Others

03 (04%)

Hematological malignancies n=78 (50%)
Acute Myeloid leukemia

25 (32%)

Acute lymphocytic leukemia

13 (17%)

Lymphoma

36 (46%)

Myeloma

01 (01%)

Others

03 (04%)

Prophylactic antibiotic

80 (51%)

GCSF

36 (23%)

Risk factor
High

116 (74)

Low

40 (26)

Profound neutropenia

65

Short latency period

74

Sepsis

30

Performance status (PS 3-4)

8

Comorbidity

3

No of high risk
1

60 (52%)

2

46 (40%)

3

9 (8%)

4

1 (0.8%)

Lines and catheters
PICC

64 (41%)

Porta Cath

19 (12%)

Indwelling catheter

1 (0.6)

PEG

2 (1%)

Culture
Gram positive

53 (34%)

Gram negative

89 (57%)

Gram positive and negative

14 (9%)

Incidence of death, 41/ 156*100 = 26.2 per 100 patients
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Table 2. Outcomes of Febrile Neutropenic Patients with
Bacteremia
Variable

Alive

Deceased

Gender
Male

66 (79%)

18 (21%)

Female

49 (68%)

23 (32%)

Malignancy
Solid

62 (79%)

16 (21%)

Hematological

53 (68%)

25 (32%)

Prophylactic antibiotics

57(71%)

23 (29%)

High

84 (72%)

32 (29%)

Low

31(78%)

09(22%)

Profound neutropenia

47

18

Short latency period

51

23

Sepsis

17

13

Performance status

6

2

Comorbidity

2

1

1

47 (78%)

13 (22%)

2

30 (65%)

16 (35%)

3

05 (56%)

04 (44%)

4

1

0

Risk criteria

No of high risk

Table 3. Bacterial Cultures
Cultures
Gram positive

41 (77%)

12 (23%)

Gram negative

64 (72%)

25 (28%)

Gram positive and negative

10 (71%)

04 (29%)

hematological malignancies 49 percent patients had
acute leukemias and 46 percent had lymphomas. Eighty
patients were already on prophylactic antibiotics while
36 patients received prophylactic granulocyte colony
stimulating factors. Overall, 116 patients fulfilled the
criteria for high risk group; 65 presenting with profound
neutropenia, 74 with short latency period, 30 with sepsis,
8 with poor performance status and 3 with co-morbid
conditions. Fifty two percent had 1 high risk factor, 40 %
had 2 high risk factors, 9% had 3 high risks factors while
1 patient had all high-risk factors. All patients harbored
either single or multiple bacterial organisms including
gram positive, gram negative or both. 34% patients had
gram positive bacteremia, 57 % with gram negative and
9 % were infected with both gram positive and negative
organisms (Table 1).
Among 73 gram positive cultures 44 % were
staphylococcus species 16 % were enterococcus and
15 % were staphylococcus aureus, whereas among 123
gram negative cultures 43 % were E. coli followed by
Aeruginosa and klebsiella 18 and 17 % respectively
(Table 4).
Outcomes
One hundred and fifteen patients recovered

Table 4. Spectrum of Bacterial Isolates
Gram positive
organism

N=73

Gram negative
organism

N=123

Staphylococcus
aureus

11(15%)

E. coli

53 (43%)

staphylococcus spp

32(44%)

P. Aureginosa

22(18%)

streptococcus spp

04(05%)

Enterobacter

02(02%)

enterococcus spp.

12(16%)

Klebsiella

18(17%)

bacillus spp.

07(10%)

Acinetobacter

10(08%)

Nocardia

03(04%)

Proteus

01(01%)

Corynebacterium

01(01%)

Salmonella

03(02%)

Other gram+ve
organism

03(04%)

Aeromonas

04(03%)

Stenotrophomonas

05(04%)

Others

05(04%)

uneventfully and discharged home. Overall mortality was
26 percent : 32 in hematological and 21 percent in solid
tumors respectively. The mean hospital stay of patients
with solid tumor and hematological Malignancies were
7.58 (SD±6.22) and 14.95(SD±11.776) days respectively.
Mortality was higher in females and in patients with
hematological malignancies i.e. 32 % (Table 2).
23 deceased patients were already on prophylactic
antibiotics at the time of presentation with febrile
neutropenia. Mortality was higher in high risk group and in
patients with both gram positive and negative bacteremia
(Table 2 and 3).

Discussion
While evaluating 156 patients with FN with bacteremia
we found 74% were high risk and mortality was slightly
higher in this category. This was similar to the result of
Carbonero et al study; patients with high risk had a higher
incidence of prolonged neutropenia and serious medical
complications and death than patients with no such risks
(Carbonero et al., 2001). This study concurred with the
previous study that the percentage of mortality gets
higher with increase in number of risk factors. However,
Carbonero’s study didn’t demonstrate whether patients
were bacteremic or not. In another study, 26% of high
risk patients were bacteremic with higher incidence of
mortality when compared with non bacteremic group
(Paesmans et al., 2007).
Majority of our bacteremic patients had acute leukemias
which followed in frequency by lymphoma and other
solid tumors. This was likely due to myelosuppressive
chemotherapy which resulted in longer duration of
neutropenia: a known risk of developing infections
(Bodey et al., 1966). The mean hospital stay in FN was
longer when compared with our contemporary study
and reported literature this could probably be due to
harboring of documented bacterial infection or high risk
group or intrinsic low immunity of patients (Osmani et
al., 2012; Berghmans et al., 2002). However, this cannot
be ascertained due to retrospective nature of study; thus,
a limitation of our study. Similarly mortality in FN with
bacteremia was 26 % with slightly higher than seen in
hematological malignancies due to prolonged neutropenia.
Asian Pacific Journal of Cancer Prevention, Vol 18
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Lal’s study, also showed that bacteremia was significantly
associated with increase length of hospital stay and
mortality (Lal et al., 2008).
The spectrum of bacterial isolates was similar to
what has been reported in both national and International
literature i.e., Coagulase negative staphylococci were the
most commonly isolated gram positive organisms (Butt et
al., 2004; Blahova et al., 2004) and Escherichia coli was
the most frequently isolated gram negative pathogen (Butt
et al ., 2004; Sigurdardottir et al., 2005; Kirby et al., 2006).
Mortality was higher in patients with both gram
positive and gram negative culture positive bacteremic
patients followed by gram negative and lastly gram
positive patients. Mortalities cannot be attributed to single
organism as few patients had polymicrobial infection.
The main concern regarding the use of prophylactic
antibiotics remains the emergence of antibiotic resistance.
There is no doubt that routine prophylactic use of
antibiotics can cause colonization of individual patients
with resistant organisms, but its clinical relevance
unclear (M Cullen et al., 2009). We observed that half
of our bacteremic patients were already on prophylactic
antibiotics (Fluoroquinolones with or without Amoxicillin
with clavulanic acid) which included all patients with
acute leukemia receiving myeloablative treatment
protocols. Despite that the mortality in this group was
29%. As death from FN is relatively rare, meta-analyses
are necessary to examine the effects of interventions on
mortality. Gafter-Gvili et al, undertook a meta- analysis
of trials comparing prophylactic antibiotic therapy
(fluoroquinolone-based and other regimens) with placebo
or no intervention in patients receiving chemotherapy.
They analysed 95 randomized controlled trials conducted
between 1973 and 2004 involving 9283 patients. The
primary outcome was all-cause mortality, and secondary
outcomes included infection-related death, febrile
episodes, bacteremia, adverse events and emergence
of bacterial resistance. This meta analysis showed a
statistically significant reduction in all causes mortality
of 34% in patients receiving prophylaxis compared
with placebo or no intervention, and a 45% reduction in
mortality in those receiving fluoroquinolones ( GafterGvili et al., 2005).
In another meta-analysis included data from GIMEMA
(Gruppo Italiano Malattie Ematologiche Maligne
dell’Adulto) and the Significant Trial, Among patients
with acute leukemia, one-third reduction as compared
with the control group, who did not receive prophylaxis.
Among patients with solid tumors and lymphomas,
fluoroquinolone prophylaxis had a significant impact on
all-cause mortality during initial cycle of chemotherapy,
with a relative risk of 0.48 (0.26–0.88), compared with
controls (Leibovici et al., 2006).
In our study, since all acute leukemia patients were
receiving prophylactic antibiotics, we did not have a
control arm to show its benefits. In a recent study patients
with low risk have shown benefits of using single agent
moxifloxacin as prophylaxis when compared with either
ciprofloxacin and Amoxicillin with clavulanic acid.
Moxifloxacin is an extended-spectrum fluoroquinolone
with a half life allowing convenient once-daily dosing.
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The drug is approved for pulmonary, skin/soft tissue,
and intra-abdominal infections in many countries. When
compared with ciprofloxacin, its antimicrobial activity
against most Gram-positive bacteria is enhanced,
whereas it has more limited activity against Pseudomonas
aeruginosa (Kern et al., 2013) .
In conclusion, we emphasize the importance of risk
stratification and continuous surveillance of the spectrum
of locally prevalent pathogens and their susceptibility
patterns which is essential for formulation of therapeutic
regimens for chemotherapy induced febrile neutropenic
patients.
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